News

Novartis and Genentech have jointly developed Lucentis, which is claimed to be the first anti-VEGF therapy approved for DME in Japan. Genentech has the commercial rights of the

EjectDelay is an US Food and Drug Administration (FDA) and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation. According

Vokanamet is a fixed-dose therapy combining canagliflozin and immediate release metformin in a single tablet. Canagliflozin, a member of a new class of drugs known as sodium glucose

Bavarian Nordic president and CEO Anders Hedegaard noted the award of this contract illustrates the strength of our MVA-BN vaccine platform technology, which has been developed through a

The patent covers the synthesis and formulation for Rockwell’s pharmaceutical-grade Triferic formula and provides protection through 18 July 2028. Additionally, the patent may be eligible for an extension

Such exclusivity extends through 25 July 2015 and is expected to be supplemented by a 30-month stay under the Hatch-Waxman Amendments that would be triggered after patent infringement

Self Regional Healthcare will support the Clemson University Center for Human Genetics with a gift of $5.6m over three years. The gift consists of an initial contribution of

This financing will fuel further international expansion, new product development and launches. It will continue to support GC Aesthetics’ vision to become the world’s leading independent medical aesthetics

Treatment will be carried out in CF patients aged six and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.